Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.